← All trials
NCT04542057
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2020
- Primary completion
- Jan 31, 2022
- Completion date
- Feb 28, 2022
- First posted
- Sep 9, 2020
- Last posted
- Dec 17, 2020
- Enrollment
- 800
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Verona Pharma plcLead sponsor
- IQVIACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.